City Research Online

Mathematical models of topically and intravitreally applied ranibizumab

Roberts, P. A. ORCID: 0000-0001-5293-6431, Thomas, C. N., Plaice, G. B. , Roberts, J. A., Jones, M-C., Andrews, J. W. & Hill, L. J. (2025). Mathematical models of topically and intravitreally applied ranibizumab. Investigative Ophthalmology and Visual Science,

Abstract

Purpose
Wet age-related macular degeneration (AMD) causes vision loss when vascular endothelial growth factor (VEGF) stimulates blood vessel growth into the light-sensitive retina. Anti-VEGF treatments such as ranibizumab are currently administered to treat wet AMD via intravitreal injections, which are unpleasant, expensive and risk complications. We explored the efficacy of topically administered ranibizumab, with cell-penetrating peptides (CPPs).

Methods
Ex vivo pig eyes were divided into 3 groups and treated with 1. topical or 2. intravitreal ranibizumab and CPP, or 3. intravitreal ranibizumab. ELISAs measured ranibizumab and VEGF concentrations in the aqueous and vitreous at 20 min, 40 min, 1 hr and 3.5 hr (n=3, per group). An ordinary differential equation model was formulated to describe the evolving concentrations of ranibizumab, VEGF and their compounds in the tear, aqueous and vitreal compartments.

Results
Experimental --- Topical: aqueous ranibizumab levels increased significantly, coincident with a significant drop in aqueous VEGF. Vitreal ranibizumab increased significantly, while vitreal VEGF remained constant. Intravitreal (with and without CPP): vitreal ranibizumab reached high concentrations, coincident with a significant drop in vitreal VEGF. Mathematical --- topical treatment may provide sustained, moderate suppression of vitreal VEGF levels, while intravitreal treatment provides strong suppression which lessens between treatments.

Conclusions
CPP allows topical ranibizumab to penetrate the cornea. Combined intravitreal/topical treatment presents a promising approach; topical treatment suppressing vitreal VEGF levels between injections and thereby potentially reducing the frequency of injections. Treatment efficacy would be enhanced if ranibizumab's rate of binding to VEGF or tear residence time could be increased.

Publication Type: Article
Subjects: Q Science > QA Mathematics
R Medicine > RE Ophthalmology
R Medicine > RM Therapeutics. Pharmacology
Departments: School of Health & Medical Sciences
School of Health & Medical Sciences > Optometry & Visual Sciences
SWORD Depositor:
[thumbnail of Roberts_et_al_2025a_IOVS_Preprint.pdf]
Preview
Text - Accepted Version
Download (10MB) | Preview
[thumbnail of Roberts_et_al_2025a_IOVS_SuppMat_Preprint.pdf]
Preview
Text - Supplemental Material
Download (12MB) | Preview
Supplementary Materials:

Export

Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Downloads

Downloads per month over past year

View more statistics

Actions (login required)

Admin Login Admin Login